The divergence between gross margin expansion and operating margin contraction suggests that FMS is capturing some pricing or mix benefits at the product level, but these are being more than offset by rising SG&A and labor costs. Net margin of 4.5% in 2026Q2 remains thin, reflecting the high fixed-cost structure and reimbursement constraints. The trend of operating margin hovering in the 8-10% range over the past two years indicates that the company has not yet regained the operating leverage it lost during the pandemic labor shock.

The persistently low ROIC, despite a stable asset turnover of 0.15x, indicates that the business is generating insufficient operating income relative to its invested capital base. The heavy goodwill load of $14.0B, representing 45% of total assets, inflates the capital base without contributing to operating earnings, dragging down returns. Even with modest deleveraging, the return on capital remains below the cost of capital, which may justify the market's deep value discount.

The elongation of the cash conversion cycle suggests that FMS is taking longer to collect from payers, likely reflecting administrative friction in U.S. healthcare billing, while paying suppliers relatively quickly. The DSO of 67 days is elevated compared to the 58 days seen in 2025Q4, indicating a potential deterioration in receivables quality or payer mix shift. This working capital drag consumes cash and may explain the volatility in free cash flow, which swung from $620M in 2025Q2 to $37M in 2026Q1.

The increase in leverage is not driven by new borrowing but by a shrinking equity base, which has been eroded by buybacks and cumulative losses. The D/EBITDA of 13.3x is extremely high, though this metric may be distorted by depressed EBITDA; interest coverage of 4.78x in 2026Q2 remains adequate but has weakened from 6.14x in 2025Q4. The reported D/E of 0.76% in the snapshot appears to be a data error, as the quarterly data consistently shows D/E around 0.8, which is more consistent with historical norms.

The declining current ratio suggests that FMS's ability to cover short-term obligations with short-term assets is weakening, though the absolute level remains above 1.0. The quick ratio of 0.75 indicates that inventory is a significant component of current assets, which may be less liquid in a stress scenario. Given the high fixed-cost structure and reliance on steady dialysis volumes, a sudden disruption in cash collections could strain liquidity, but the stable cash flow generation provides some cushion.